JP2022537047A5 - - Google Patents
Info
- Publication number
- JP2022537047A5 JP2022537047A5 JP2021575482A JP2021575482A JP2022537047A5 JP 2022537047 A5 JP2022537047 A5 JP 2022537047A5 JP 2021575482 A JP2021575482 A JP 2021575482A JP 2021575482 A JP2021575482 A JP 2021575482A JP 2022537047 A5 JP2022537047 A5 JP 2022537047A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- pharmaceutically acceptable
- administration
- acceptable salt
- agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962863406P | 2019-06-19 | 2019-06-19 | |
| US62/863,406 | 2019-06-19 | ||
| PCT/IB2020/055653 WO2020254985A1 (en) | 2019-06-19 | 2020-06-17 | Pyrido[2,3-d]pyrimidine derivatives as inhibitors of human immunodeficiency virus replication |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022537047A JP2022537047A (ja) | 2022-08-23 |
| JP2022537047A5 true JP2022537047A5 (cg-RX-API-DMAC7.html) | 2023-06-21 |
| JP7628512B2 JP7628512B2 (ja) | 2025-02-10 |
Family
ID=71738195
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021575482A Active JP7628512B2 (ja) | 2019-06-19 | 2020-06-17 | ヒト免疫不全ウイルス複製の阻害剤としてのピリド[2,3-d]ピリミジン誘導体 |
Country Status (33)
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA53973A (fr) | 2018-10-24 | 2022-02-09 | Viiv Healthcare Uk No 5 Ltd | Inhibiteurs de la réplication du virus de l'immunodéficience humaine |
| EP3986561B1 (en) | 2019-06-19 | 2024-02-14 | VIIV Healthcare UK (No.5) Limited | Pyrido[2,3-d]pyrimidine derivatives as inhibitors of human immunodeficiency virus replication |
| US12415771B2 (en) | 2019-06-19 | 2025-09-16 | Nmd Pharma A/S | Compounds for the treatment of neuromuscular disorders |
| AU2020358156B2 (en) * | 2019-10-01 | 2024-06-06 | Janssen Sciences Ireland Unlimited Company | Method for treating HIV with cabotegravir and rilpivirine |
| IL293566A (en) * | 2019-12-09 | 2022-08-01 | Viiv Healthcare Co | Pharmaceutical preparations containing Cabotgravir |
| WO2021176366A1 (en) * | 2020-03-06 | 2021-09-10 | VIIV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
| US12703699B2 (en) | 2020-03-06 | 2026-08-11 | Viiv Healthcare Uk (No. 5) Limited | Inhibitors of human immunodeficiency virus replication |
| EP4135702B1 (en) * | 2020-04-15 | 2026-06-03 | VIIV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
| AU2022362855B2 (en) * | 2021-10-13 | 2025-08-14 | VIIV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
| TW202448483A (zh) | 2023-05-31 | 2024-12-16 | 美商基利科學股份有限公司 | 用於hiv之治療性化合物 |
| AR132951A1 (es) | 2023-06-15 | 2025-08-13 | Viiv Healthcare Uk No 5 Ltd | Métodos e intermedios para preparar compuestos |
| WO2025169059A1 (en) | 2024-02-05 | 2025-08-14 | VIIV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030207910A1 (en) | 2001-02-02 | 2003-11-06 | Tao Wang | Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives |
| PL364279A1 (en) | 2001-02-02 | 2004-12-13 | Bristol-Myers Squibb Company | Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives |
| US8318732B2 (en) * | 2008-07-02 | 2012-11-27 | Avexa Limited | Compounds having antiviral properties |
| CN102464654B (zh) | 2010-11-12 | 2016-01-13 | 上海泓博智源医药技术有限公司 | 抗病毒化合物 |
| CA2840095A1 (en) | 2011-07-06 | 2013-01-10 | Gilead Sciences, Inc. | Compounds for the treatment of hiv |
| CN102863512B (zh) | 2011-07-07 | 2016-04-20 | 上海泓博智源医药技术有限公司 | 抗病毒化合物 |
| US9220710B2 (en) | 2013-01-09 | 2015-12-29 | Gilead Sciences, Inc. | Therapeutic compounds |
| TW201443037A (zh) | 2013-01-09 | 2014-11-16 | Gilead Sciences Inc | 治療用化合物 |
| EP2943493B1 (en) | 2013-01-09 | 2017-08-02 | Gilead Sciences, Inc. | Therapeutic compounds for the treatment of viral infections |
| TWI694071B (zh) | 2013-03-01 | 2020-05-21 | 美商基利科學股份有限公司 | 治療反轉錄病毒科(Retroviridae)病毒感染之治療性化合物 |
| WO2015130964A1 (en) | 2014-02-28 | 2015-09-03 | Gilead Sciences, Inc. | Therapeutic compounds |
| WO2015130966A1 (en) | 2014-02-28 | 2015-09-03 | Gilead Sciences, Inc. | Antiviral agents |
| US9873680B2 (en) | 2014-08-29 | 2018-01-23 | Gilead Sciences, Inc. | Therapeutic compounds |
| LT3347352T (lt) * | 2016-08-19 | 2019-08-12 | Gilead Sciences, Inc. | Terapiniai junginiai, naudotini živ viruso infekcijos profilaktikai arba terapiniam gydymui |
| WO2018045150A1 (en) * | 2016-09-02 | 2018-03-08 | Gilead Sciences, Inc. | 4,6-diamino-pyrido[3,2-d]pyrimidine derivaties as toll like receptor modulators |
| TW201906834A (zh) * | 2017-05-02 | 2019-02-16 | 英商Viiv醫療保健英國(No.5)有限公司 | 人類免疫不全病毒複製之抑制劑 |
| MA53973A (fr) * | 2018-10-24 | 2022-02-09 | Viiv Healthcare Uk No 5 Ltd | Inhibiteurs de la réplication du virus de l'immunodéficience humaine |
| UY38559A (es) * | 2019-02-01 | 2020-07-31 | Viiv Healthcare Uk No 5 Ltd | Inhibidores de la replicación del virus de la inmunodeficiencia humana |
| EP3986561B1 (en) | 2019-06-19 | 2024-02-14 | VIIV Healthcare UK (No.5) Limited | Pyrido[2,3-d]pyrimidine derivatives as inhibitors of human immunodeficiency virus replication |
-
2020
- 2020-06-17 EP EP20743783.1A patent/EP3986561B1/en active Active
- 2020-06-17 MA MA56526A patent/MA56526B1/fr unknown
- 2020-06-17 PT PT207437831T patent/PT3986561T/pt unknown
- 2020-06-17 MY MYPI2021007563A patent/MY206712A/en unknown
- 2020-06-17 MX MX2021016149A patent/MX2021016149A/es unknown
- 2020-06-17 PH PH1/2021/553180A patent/PH12021553180A1/en unknown
- 2020-06-17 TW TW109120334A patent/TWI850403B/zh active
- 2020-06-17 BR BR112021025655A patent/BR112021025655A2/pt unknown
- 2020-06-17 AU AU2020295793A patent/AU2020295793B2/en active Active
- 2020-06-17 ES ES20743783T patent/ES2974541T3/es active Active
- 2020-06-17 HU HUE20743783A patent/HUE065762T2/hu unknown
- 2020-06-17 WO PCT/IB2020/055653 patent/WO2020254985A1/en not_active Ceased
- 2020-06-17 UY UY0001038755A patent/UY38755A/es unknown
- 2020-06-17 MD MDE20220479T patent/MD3986561T2/ro unknown
- 2020-06-17 LT LTEPPCT/IB2020/055653T patent/LT3986561T/lt unknown
- 2020-06-17 PL PL20743783.1T patent/PL3986561T3/pl unknown
- 2020-06-17 US US17/268,107 patent/US12129255B2/en active Active
- 2020-06-17 PE PE2021002114A patent/PE20220510A1/es unknown
- 2020-06-17 KR KR1020227001501A patent/KR102932817B1/ko active Active
- 2020-06-17 IL IL288750A patent/IL288750B2/en unknown
- 2020-06-17 CN CN202080052305.0A patent/CN114245795B/zh active Active
- 2020-06-17 SM SM20240153T patent/SMT202400153T1/it unknown
- 2020-06-17 RS RS20240309A patent/RS65304B1/sr unknown
- 2020-06-17 SI SI202030385T patent/SI3986561T1/sl unknown
- 2020-06-17 AR ARP200101700A patent/AR119174A1/es unknown
- 2020-06-17 UA UAA202200207A patent/UA128967C2/uk unknown
- 2020-06-17 CN CN202410979514.XA patent/CN119039288A/zh active Pending
- 2020-06-17 JP JP2021575482A patent/JP7628512B2/ja active Active
- 2020-06-17 CR CR20210664A patent/CR20210664A/es unknown
- 2020-06-17 DK DK20743783.1T patent/DK3986561T3/da active
- 2020-06-17 FI FIEP20743783.1T patent/FI3986561T3/fi active
- 2020-06-17 HR HRP20240501TT patent/HRP20240501T1/hr unknown
-
2021
- 2021-12-17 CL CL2021003388A patent/CL2021003388A1/es unknown
- 2021-12-20 CO CONC2021/0017479A patent/CO2021017479A2/es unknown
-
2024
- 2024-09-18 US US18/888,497 patent/US20250019383A1/en active Pending